Risk-Based Monitoring

Recent analysis showed 81% of clinical trial sites using RBQM statistical data monitoring experienced an improvement in quality.

A review of industry methods and adoption trends in those trial segments.

Moving towards the development of mature quality management systems.

Webinar Date/Time: Tuesday, December 10th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

The need to boost education, shift culture, and embrace new technologies.

Webinar Date/Time: Tuesday, November 12th, 2024 at 10am EST | 7am PST | 3pm GMT | 4pm CET

Webinar Date/Time: Thursday, September 19th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST

Webinar Date/Time: Tuesday, September 10th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST

Under the new extension, FDA and CluePoints will enhance CluePoints’ SMART software to address a broader range of regulatory concerns.

In the fifth and final part of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints look ahead to the future of risk-based quality management and what adoption will look like.

In part 4 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints touch on what risks companies leave themselves susceptible to without the adoption of risk-based approaches.

In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.

In part 2 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints highlight what stood out to them from the results of a recent study on RBQM adoption.

In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.

A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.

Analysis assesses the relative percentage of quality issues detected via SDM that clinical study teams considered critical.

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

Webinar Date/Time: Thursday, March 14th, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

Study teams often face challenges in maintaining detailed and accurate documentation of risk signals.

Site and project management teams play major roles in risk-management and monitoring performance.

Webinar Date/Time: Tue, Oct 17, 2023 11:00 AM EDT

Overall rate of significant KRI results for sites located in Ukraine has consistently risen since 2021.

Collaboration and regulation were the watchwords at DIA Global this year, where the ICH E6(R3) guideline, published in final draft form in May, was the talk of the congress.

Study Health Check provides early identification of issues related to protocol deviations and determines objective measures of site-specific versus study-wide performance.

Metric derived from CluePoints central monitoring platform assesses average total cycle time from risk signal creation until closure.

Strategies for intervention—or, ideally, averting potential pitfalls from the onset.

Statistical methods used via this technique in centralized monitoring.

Webinar Date/Time: Option 1: Thursday, May 11th, 2023 at 9am EDT | 6am PDT | 2pm BST | 3pm CEST Option 2: Thursday, May 11th, 2023 at 2pm EDT | 11am PDT | 7pm BST | 8pm CEST

As challenges like regulatory adherence, cost, and timelines become more complex, sponsors are seeking out new ways to incorporate risk-based approaches.